Last update July 16, 2022

N02CD06

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a calcitonin gene-related peptide receptor antagonist. It is ndicated for the treatment of migraine. Oral administration once daily.

Its pharmacokinetic data (high percentage of protein binding, large volume of distribution and moderately high molecular weight) explain the negligible passage into breast milk observed. (Baker 2022)

Expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed)

 

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

N02CD06 is Rimegepant in ATC Code/s.

Is written in other languages:

Group

N02CD06 belongs to this group or family:

Tradenames

Main tradenames from several countries containing N02CD06 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 64 %
Molecular weight 535 daltons
Protein Binding 96 %
VD 1.7 l/Kg
pKa 10.7 -
Tmax 1.5 hours
11 hours
M/P ratio 0.2 -
Theoretical Dose 0.005 mg/Kg/d
Relative Dose 0.51 %

References

  1. Baker TE, Croop R, Kamen L, Price P, Stock DA, Ivans A, Bhardwaj R, Anderson MS, Madonia J, Stringfellow J, Bertz R, Coric V, Hale TW. Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women. Breastfeed Med. 2022 Mar;17(3):277-282. Consulted on April 5, 2022 Abstract Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on March 17, 2022 Full text (link to original source)
  3. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on March 15, 2022 Full text (link to original source)
  4. FDA. Rimegepant (Nurtec) Drug Summary. 2020 Full text (in our servers)

Total visits

121

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM